Cargando…
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Until recently, there were no true innovations in the management of locally advanced (aUC) and metastatic urothelial cancer (mUC) in the last three decades. Vinflunine has been approved by the EMA (European Medicines Agency) with only limited improvement compared to best supportive care in second li...
Autores principales: | Resch, Irene, Shariat, Shahrokh F., Gust, Kilian M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862914/ https://www.ncbi.nlm.nih.gov/pubmed/29606979 http://dx.doi.org/10.1007/s12254-018-0396-y |
Ejemplares similares
-
Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature
por: Gust, Kilian M., et al.
Publicado: (2021) -
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
por: Soria, Francesco, et al.
Publicado: (2018) -
PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis
por: Tan, Wei Phin, et al.
Publicado: (2019) -
Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma
por: Mullane, Stephanie A., et al.
Publicado: (2016) -
Alterations of DNA damage response genes correlate with response and overall survival in anti‐PD‐1/PD‐L1‐treated advanced urothelial cancer
por: Joshi, Monika, et al.
Publicado: (2020)